share_log

bluebird bio | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(8.0%)

bluebird bio | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(8.0%)

bluebird bio | SC 13G:超过5%持股股东披露文件-BlackRock, Inc.(8.0%)
美股SEC公告 ·  2024/10/23 03:30

Moomoo AI 已提取核心信息

On September 30, 2024, BlackRock, Inc., a Delaware-based investment management corporation, filed a Schedule 13G with the Securities and Exchange Commission (SEC), disclosing an 8.0% ownership stake in bluebird bio, a biotechnology company. The filing indicates that BlackRock has sole dispositive power over 15,443,767 shares of bluebird bio's common stock. This stake does not grant BlackRock any sole voting power, as indicated in the filing. The Schedule 13G is a regulatory filing that is required when a party acquires more than 5% of a company's stock and is used to declare the acquisition and ownership status of the filer. The filing was certified by Spencer Fleming, Attorney-In-Fact for BlackRock, Inc., and was dated October 22, 2024.
On September 30, 2024, BlackRock, Inc., a Delaware-based investment management corporation, filed a Schedule 13G with the Securities and Exchange Commission (SEC), disclosing an 8.0% ownership stake in bluebird bio, a biotechnology company. The filing indicates that BlackRock has sole dispositive power over 15,443,767 shares of bluebird bio's common stock. This stake does not grant BlackRock any sole voting power, as indicated in the filing. The Schedule 13G is a regulatory filing that is required when a party acquires more than 5% of a company's stock and is used to declare the acquisition and ownership status of the filer. The filing was certified by Spencer Fleming, Attorney-In-Fact for BlackRock, Inc., and was dated October 22, 2024.
2024年9月30日,总部位于特拉华州的贝莱德股份有限公司向证券交易委员会(SEC)提交了一份13G表格,公开了其对生物技术公司bluebird bio的8.0%持股。该申报显示,贝莱德对bluebird bio的普通股拥有1543.767万股的唯一决策权。这一持股并不赋予贝莱德任何唯一的表决权,正如文件中所示。13G表是一种监管申报,当一方收购某公司股份超过5%时需要提交,用于声明申报人的收购和所有权状况。该申报由贝莱德股份有限公司的代理人斯宾塞·弗莱明律师签署,并于2024年10月22日日期。
2024年9月30日,总部位于特拉华州的贝莱德股份有限公司向证券交易委员会(SEC)提交了一份13G表格,公开了其对生物技术公司bluebird bio的8.0%持股。该申报显示,贝莱德对bluebird bio的普通股拥有1543.767万股的唯一决策权。这一持股并不赋予贝莱德任何唯一的表决权,正如文件中所示。13G表是一种监管申报,当一方收购某公司股份超过5%时需要提交,用于声明申报人的收购和所有权状况。该申报由贝莱德股份有限公司的代理人斯宾塞·弗莱明律师签署,并于2024年10月22日日期。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息